PD0325901

Licensed by Pfizer Catalog No.S1036

Molecular Weight(MW): 482.19

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

Cited by 138 Publications

Nat Med, 2019, 25(1):130-140

PubMed: 30510251 ( click the link to review the publication )

Nature, 2018, 553(7686):96-100

PubMed: 29258294 ( click the link to review the publication )

Cell, 2018, 174(2):406-421

PubMed: 29887375 ( click the link to review the publication )

Cell Stem Cell, 2018, 23(3):382-395

PubMed: 30100166 ( click the link to review the publication )

Cell Stem Cell, 2018, 23(5):727-741

PubMed: 30220521 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(5):720-731

PubMed: 28343982 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):748-760

PubMed: 29232553 ( click the link to review the publication )

Nature, 2016, 539(7629):452-455

PubMed: 27783602 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14413

PubMed: 25945737 ( click the link to review the publication )

Nature, 2015, 517(7534):391-5

PubMed: 25409143 ( click the link to review the publication )

Cell, 2015, 160(1-2):161-76

PubMed: 25594179 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Nat Methods , 2011, 8(6):487-93

PubMed: 21516115 ( click the link to review the publication )

Mol Psychiatry, 2019, 10.1038/s41380-018-0325-9

PubMed: 30696942 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.41627

PubMed: 30860479 ( click the link to review the publication )

Cell Death Discov, 2019, 5:104

PubMed: 31240131 ( click the link to review the publication )

Development, 2019, 146(14)

PubMed: 31320324 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):642-655

PubMed: 30679390 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31270153 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-19-0077

PubMed: 31217166 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(5):3629-3640

PubMed: 30907509 ( click the link to review the publication )

CNS Neurosci Ther, 2019, 25(6):759-771

PubMed: 30720246 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )
Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0211134

PubMed: 30917119 ( click the link to review the publication )

DNA Cell Biol, 2019, 38(5):410-422

PubMed: 30896984 ( click the link to review the publication )

PeerJ, 2019, 10.7717/peerj.6314

PubMed: 30713819 ( click the link to review the publication )

Methods Mol Biol, 2019, 2005:101-124

PubMed: 31175649 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5078

PubMed: 30510260 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(19):4771-4784

PubMed: 29563139 ( click the link to review the publication )

Dev Cell, 2018, 45(4):526-536

PubMed: 29787711 ( click the link to review the publication )

Cancer Res, 2018, 78(2):436-450

PubMed: 29150430 ( click the link to review the publication )

J Immunol, 2018, 200(7):2372-2390

PubMed: 29475988 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(2)

PubMed: 29419748 ( click the link to review the publication )

J Biol Chem, 2018, 293(30):11913-11927

PubMed: 29899110 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2018, 59(1):462-471

PubMed: 29368005 ( click the link to review the publication )

Stem Cells Dev, 2018, 27(21):1479-1493

PubMed: 30091687 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):535-549

PubMed: 29466914 ( click the link to review the publication )

Cell Cycle, 2018, 17(12):1487-1495

PubMed: 30045656 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 500(4):958-965

PubMed: 29709476 ( click the link to review the publication )

Mol Med Rep, 2018, 17(4):4999-5006

PubMed: 29393439 ( click the link to review the publication )

Methods Mol Biol, 2018, 1649:473-488

PubMed: 29130217 ( click the link to review the publication )

Blood, 2017, 129(12):1691-1701

PubMed: 28159742 ( click the link to review the publication )

Nat Protoc, 2017, 12(10):2097-2109

PubMed: 28880277 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(21):6567-6579

PubMed: 28765329 ( click the link to review the publication )

Dev Cell, 2017, 41(3):274-286

PubMed: 28457793 ( click the link to review the publication )
Cancer Res, 2017, 77(7):1599-1610

PubMed: 28202513 ( click the link to review the publication )

Cell Rep, 2017, 18(13):3167-3177

PubMed: 28355568 ( click the link to review the publication )

Stem Cells Transl Med, 2017, 6(2):340-351

PubMed: 28191784 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

PLoS One, 2017, 12(4):e0176120

PubMed: 28419157 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0183343

PubMed: 28817661 ( click the link to review the publication )

Methods Mol Biol, 2017, 1487:163-174

PubMed: 27924566 ( click the link to review the publication )

Oncotarget, 2017, 8(24):39460-39475

PubMed: 28467801 ( click the link to review the publication )

Oncotarget, 2017, 8(20):32977-32989

PubMed: 28380429 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47574-47585

PubMed: 28548933 ( click the link to review the publication )

Cell, 2017, 168(3):473-486

PubMed: 28129541 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(44):12478-12483

PubMed: 27738243 ( click the link to review the publication )

Cell Death Differ, 2016, 23(3):430-41

PubMed: 26292757 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:68

PubMed: 27084680 ( click the link to review the publication )

FASEB J, 2016, 31(3):1046-1058

PubMed: 27920151 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )

Cell Tissue Res, 2016, 364(2):429-41

PubMed: 26613602 ( click the link to review the publication )

FEBS Lett, 2016, 590(19):3416-3424

PubMed: 27597178 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 11(7):e0158655

PubMed: 27384321 ( click the link to review the publication )

PLoS One, 2016, 11(6):e0158046

PubMed: 27336671 ( click the link to review the publication )

J Surg Res, 2016, 206(2):371-379

PubMed: 27884331 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4767-76

PubMed: 26518767 ( click the link to review the publication )
Methods Mol Biol, 2016, 1480:153-65

PubMed: 27659983 ( click the link to review the publication )

EMBO Rep, 2015, 16(1):87-96

PubMed: ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.97

PubMed: 25867065 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

FASEB J, 2015, 10.1096/fj.14-267278

PubMed: 25857555 ( click the link to review the publication )

Stem Cells, 2015, 10.1002/stem.1990

PubMed: 25788415 ( click the link to review the publication )

Stem Cells, 2015, 33(3):686-98

PubMed: ( click the link to review the publication )

J Thromb Haemost, 2015, 10.1111/jth.12954

PubMed: 25858425 ( click the link to review the publication )

Int J Biol Sci, 2015, 11(4):411-422

PubMed: ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )

Biol Reprod, 2015, 10.1095/biolreprod.114.127647

PubMed: 25947060 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0119387

PubMed: 25803847 ( click the link to review the publication )

Cell Biology International Reports, 2015, 10.1002/cbi3.10019

PubMed: ( click the link to review the publication )

Nature, 2015, 521(7551):232-6

PubMed: 25915022 ( click the link to review the publication )

Blood, 2014, 123(18):2838-42

PubMed: 24553178 ( click the link to review the publication )

J Exp Med, 2014, 211(3):395-404

PubMed: 24516119 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(9):2410-23

PubMed: 24573550 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(29):10678-83

PubMed: 25002522 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1319738111

PubMed: 24623855 ( click the link to review the publication )

Kidney Int, 2014, 10.1038/ki.2014.107

PubMed: 24786704 ( click the link to review the publication )

Oncogene, 2014, 33(14):1828-39

PubMed: 23624914 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(8):2073-80

PubMed: 24899684 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):3098-106

PubMed: 25253779 ( click the link to review the publication )
J Bone Joint Surg Am, 2014, 96(14):e117

PubMed: 25031379 ( click the link to review the publication )

J Immunol, 2014, 192(4):1351-5

PubMed: 24442443 ( click the link to review the publication )

J Biol Chem, 2014, 10.1074/jbc.M114.580076

PubMed: 25301940 ( click the link to review the publication )

Cell Signal, 2014, 26(10):2276-2283

PubMed: 24905473 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(17):2030-45

PubMed: 24742229 ( click the link to review the publication )

Biol Reprod, 2014, 91(4):88

PubMed: 25210127 ( click the link to review the publication )

Pancreas, 2014, 43(1):88-92

PubMed: 24263107 ( click the link to review the publication )

PLoS One, 2014, 9(4):e92304

PubMed: 24743237 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85089

PubMed: 24465482 ( click the link to review the publication )

Theriogenology, 2014, 82(2):283-93

PubMed: 24853281 ( click the link to review the publication )

Mol Med Rep, 2014, 10.3892/mmr.2014.2793

PubMed: 25352256 ( click the link to review the publication )

Oncotarget, 2014, 5(23):12189-202

PubMed: 25361008 ( click the link to review the publication )

Oncotarget, 2014, 5(2):351-62.

PubMed: 24504051 ( click the link to review the publication )

Blood, 2013, 122,215045

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(10):4015-20

PubMed: 23431193 ( click the link to review the publication )

Stem Cell Rep, 2013, 1(4):360-9

PubMed: 24319670 ( click the link to review the publication )

Development, 2013, 140(14):2961-71

PubMed: 23760955 ( click the link to review the publication )

Bone, 2013, 59:151-61

PubMed: 24269278 ( click the link to review the publication )

Eur Cell Mater, 2013, 26:208-21

PubMed: 24146213 ( click the link to review the publication )

Exp Cell Res, 2013, 319(19):2928-37

PubMed: 24080014 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81156

PubMed: 24339907 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56518

PubMed: 23437152 ( click the link to review the publication )

Cancer Res, 2012, 72(13):3350-9

PubMed: 22573716 ( click the link to review the publication )

Cancer Lett, 2012, 324(1):98-108

PubMed: 22579651 ( click the link to review the publication )
Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

Br J Haematol, 2012, 159(4):430-40

PubMed: 22985491 ( click the link to review the publication )

Radiother Oncol, 2012, 105(1):64-71

PubMed: 22682746 ( click the link to review the publication )

J Genet Genomics, 2012, 39(12):643-51

PubMed: 23273768 ( click the link to review the publication )

Cell Signal, 2012, 24(12):2360-8

PubMed: 22917534 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(14):2606-12

PubMed: 22455749 ( click the link to review the publication )

Mol Cell, 2011, 43(5):723-37

PubMed: 21884975 ( click the link to review the publication )

Oncogene, 2011, 30(11):1341-50

PubMed: 21057530 ( click the link to review the publication )

J Bone Miner Res, 2011, 26(10):2486-97

PubMed: 21812026 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(2):R36

PubMed: 21457548 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

J Biol Chem, 2011, 286(24):21062-72

PubMed: 21489997 ( click the link to review the publication )

Pharm Res, 2011, 28(12):3069-78

PubMed: 21879387 ( click the link to review the publication )

PLoS One, 2011, 6(10):e26755

PubMed: 22046344 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

J Biol Chem, 2010, 285(42):32370-7

PubMed: 20696763 ( click the link to review the publication )

Genes Cancer, 2010, 1(10):994-1007

PubMed: 21442024 ( click the link to review the publication )

Cancer Res, 2009, 69(17):6839-47

PubMed: 19706763 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

Targets

MEK ^[1]
(Cell-free assay)

0.33 nM

In vitro

PD0325901 shows higher permeability than CI-1040, another MEK inhibitor. PD0325901 should be able to achieve higher systemic exposures than CI-1040. ^[1] PD0325901 is exquisitely specific and highly potent against purified MEK, revealing a K_i^app of 1 nM against activated MEK1 and MEK2. ^[2] PD0325901 is roughly 500-fold more potent than CI-1040 with respect to its cellular effects on phosphorylation of ERK1 and ERK2, displaying subnanomolar activity. ^[2] PD0325901 prevents the growth of melanoma cell lines. PD0325901 inhibits the growth of TPC-1 cells and K2 cells with GI50 of 11 nM and 6.3 nM, respectively. ^[3] PD0325901 significantly prevents the the growth of PTC cells harboring a BRAF mutation at very low concentration (10 nM) and only moderately increases the growth of the PTC cells carrying the RET/PTC1 rearrangement at the same concentration. PD0325901 effectively inhibits the phosphorylation of ERK1/2 in multiple PTC cell lines. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human CHP-212 cell	M1;zfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzPyCwTT6=	MkjRV2FPT0WU
human M14 cell	NVfxe3ByT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MVvJcohq[mm2aX;uJI9nKGi3bXHuJG0yPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwNEWgcm0v	M3nHb3NCVkeHUh?=
human SK-MEL-28 cell	MoLIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M1\pXGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53MjDuUU4>	MVTTRW5ITVJ?
human NOMO-1 cell	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXXJcohq[mm2aX;uJI9nKGi3bXHuJG5QVU9vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNFchdk1w	NWDORpBvW0GQR1XS
human A375 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXzJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[5JI5ONg>?	NYTodolEW0GQR1XS
human DU-4475 cell	MkPMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NIqz[ZNKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O\|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV5IH7NMi=>	NUHmWXZXW0GQR1XS
human C32 cell	NF7ac3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M2TMWGlvcGmkaYTpc44hd2ZiaIXtZY4hSzN{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz62O{BvVS5?	NVPpUHFqW0GQR1XS
human BPH-1 cell	NIfoTpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NEH5XVdKdmirYnn0bY9vKG:oIHj1cYFvKEKSSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{46PSCwTT6=	Mnq0V2FPT0WU
human CP50-MEL-B cell	NYnFT4hWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M2rZemlvcGmkaYTpc44hd2ZiaIXtZY4hS1B3MD3NSWwuSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwNUigcm0v	Mo\OV2FPT0WU
human H9 cell	NILOclZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			Mly2TY5pcWKrdHnvckBw\iCqdX3hckBJQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwN{egcm0v	NFGxfnZUSU6JRWK=
human HTC-C3 cell	NGr6fnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MkK2TY5pcWKrdHnvckBw\iCqdX3hckBJXENvQ{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg6KG6PLh?=	NWHz[odEW0GQR1XS
human BHT-101 cell	NWXKTW9mT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlchdk1w	NUC2PHlOW0GQR1XS
human COLO-741 cell	M1XYT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NEixZ3BKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO\|QyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5zIH7NMi=>	MXvTRW5ITVJ?
human OVCAR-5 cell	MlS2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NIi4bXZKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04Njh{IH7NMi=>	MnXhV2FPT0WU
human A549 cell	NVnDcmJTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MVrJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki5JI5ONg>?	M1T2VHNCVkeHUh?=
human SH-4 cell growth	NW\qS4hDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NF;mUpJKdmirYnn0bY9vKG:oIHj1cYFvKFOKLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI3KG6PLh?=	M{WzRXNCVkeHUh?=
human SK-N-AS cell	M1j2[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlQ1KG6PLh?=	NUDNPFZ3W0GQR1XS
human HT-144 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF2NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUiuPVchdk1w	NFHQVINUSU6JRWK=
human MEL-HO cell	M1TCfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NYXNe5lWUW6qaXLpeIlwdiCxZjDoeY1idiCPRVytTG8h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7NMi=>	Mn;jV2FPT0WU
human COLO-679 cell	M4XQUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M4jVT2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yMTDuUS=>	M3PjTnNCVkeHUh?=
human HuP-T4 cell	NF3RdndIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MkjCTY5pcWKrdHnvckBw\iCqdX3hckBJfVBvVESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE46QCCwTT6=	NVK2SY5PW0GQR1XS
human H-EMC-SS cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MoXGTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjB{IH7NMi=>	MmqyV2FPT0WU
human LB2518-MEL cell	Mn;4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NEXsPG5KdmirYnn0bY9vKG:oIHj1cYFvKEyEMkWxPE1OTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6xN{BvVS5?	MX;TRW5ITVJ?
human HL-60 cell	M1;Sdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NHvYeoFKdmirYnn0bY9vKG:oIHj1cYFvKEiOLU[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOTVibl2u	MnjvV2FPT0WU
human NCI-H1666 cell	NUTwVZB[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NHTIeJVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY3PiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFzLkG3JI5ONg>?	M3;BcHNCVkeHUh?=
human A101D cell	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NUnTcZZCUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjR3IH7NMi=>	M{TkbXNCVkeHUh?=
human RVH-421 cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M2TXSmlvcGmkaYTpc44hd2ZiaIXtZY4hWl[KLUSyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzNjZ2IH7NMi=>	MYLTRW5ITVJ?
human Hs-578-T cell	NYjORpQ4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NEDPd\|dKdmirYnn0bY9vKG:oIHj1cYFvKEi\|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTJwN{mgcm0v	MVPTRW5ITVJ?
human A375 cells	M4f2UnBzd2yrZnXyZZRqd25iYYPzZZk>		NVTqcYNIPzJiaB?=	M363T2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDlfJBz\XO\|aX7nJGJTSUZiVk[wNGUhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtKHSrdHXyMYdtdyCjc4PhfUwhUUN3ME2xN{BvVS5?	Ml\1NlM1PzR\|OEi=
human DOK cell	Moq4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NGPoPVlKdmirYnn0bY9vKG:oIHj1cYFvKESRSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGzMlQhdk1w	NFe0eWxUSU6JRWK=
human Mewo cell	NFX3OotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG1mf29iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zND60OUBvVS5?	MmLvV2FPT0WU
human ONS-76 cell	MlPsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M2jaPWlvcGmkaYTpc44hd2ZiaIXtZY4hV06VLUe2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPTFibl2u	MVfTRW5ITVJ?
human UACC-257 cell	NUnlNVQxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M3vTNWlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQz2yOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPC54MjDuUU4>	MUTTRW5ITVJ?
human SW626 cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M4\rcWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4Mk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE46OSCwTT6=	NHf1bI5USU6JRWK=
human SW620 cell	M1y3bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNYPjJyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUSuPVUhdk1w	NUDNNVFiW0GQR1XS
human TYK-nu cell	Mle2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NEXvfpZKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjF\|IH7NMi=>	MY\TRW5ITVJ?
human ACN cell	M37ZOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M3rMbmlvcGmkaYTpc44hd2ZiaIXtZY4hSUOQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUWuO\|Yhdk1w	NUfWWVR5W0GQR1XS
human MIAPaCa2 cells	NEHIUmNRem:uaX\ldoF1cW:wIHHzd4F6			NGjleXRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3JRXBiS2F{IHPlcIx{NCCLQ{WwQVE4KG6PLh?=	NH\Z[YIzOzR5NEO4PC=>
human T-24 cell	NInOTIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MoP3TY5pcWKrdHnvckBw\iCqdX3hckBVNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUmuO\|Ehdk1w	M2DMUXNCVkeHUh?=
human AGS cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXLJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJyLkSxJI5ONg>?	M3\ydHNCVkeHUh?=
human SW872 cell	NIXlXo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NIf2R4ZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvQTlibl2u	Mkf3V2FPT0WU
human C2BBe1 cell	Mmr4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MoS4TY5pcWKrdHnvckBw\iCqdX3hckBEOkKEZUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE42PCCwTT6=	NH30VotUSU6JRWK=
human MZ7-mel cell	MlW1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NVnkPI97UW6qaXLpeIlwdiCxZjDoeY1idiCPWketcYVtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjlwNEOgcm0v	MV;TRW5ITVJ?
human HCC2998 cell	MoDGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M4q0VWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMkm5PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM{NjZ4IH7NMi=>	MlvwV2FPT0WU
human HO-1-N-1 cell	MojOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MkPFTY5pcWKrdHnvckBw\iCqdX3hckBJVy1zLV6tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR\|IH7NMi=>	NHf6[ZFUSU6JRWK=
human SW756 cell	NF\Xd2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NXTUTlhsUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR3IH7NMi=>	NVjVVG4xW0GQR1XS
human NCI-H1437 cell	Mm\WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NE[4NXZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVQ{PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTN2LkS5JI5ONg>?	MXLTRW5ITVJ?
human NCI-H747 cell	M3exfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M{DGWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3OFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PC57ODDuUU4>	MV;TRW5ITVJ?
human SK-MEL-2 cell	MlLsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NVzUU3BzUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTN3LkKgcm0v	NWqzbVdFW0GQR1XS
human MZ2-MEL cell	NVLGWJIxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MXPJcohq[mm2aX;uJI9nKGi3bXHuJG1bOi2PRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOU43PSCwTT6=	Mn\3V2FPT0WU
human PSN1 cell	M{TI[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NYnIVIRxUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N\|gvPDVibl2=	M4\CfXNCVkeHUh?=
human CAL-39 cell	M3XldGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NEHy[VVKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM6NjB2IH7NMi=>	NXPES491W0GQR1XS
human LOXIMVI cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPU4{QSCwTT6=	NIPUcZhUSU6JRWK=
human COLO-792 cell	NGTKbVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NWfQcm42UW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTR\|LkG1JI5ONg>?	NFPwPFhUSU6JRWK=
human CAL-27 cell	NUnYZo92T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NES1OZNKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2yO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ1NjlzIH7N	MmDuV2FPT0WU
human AsPC-1 cell	M4PkT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MlLXTY5pcWKrdHnvckBw\iCqdX3hckBCe1CFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20OU4zQCCwTT6=	M3q2cnNCVkeHUh?=
human NCI-H2291 cell	MkPWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NXvRN3NtUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIzQTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Nj60OkBvVS5?	NFzJNXVUSU6JRWK=
human RCM-1 cell	M3HsVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NVLyN41EUW6qaXLpeIlwdiCxZjDoeY1idiCUQ12tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ3Njh3IH7NMi=>	NI\0W\|RUSU6JRWK=
human NCI-H292 cell	MkLyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MlzRTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ4NjN7IH7NMi=>	Mk\pV2FPT0WU
human WM-115 cell	M13EUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MkLpTY5pcWKrdHnvckBw\iCqdX3hckBYVS1zMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20PE42KG6PLh?=	MmjrV2FPT0WU
human RT-112 cell	NXu0WYdWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M{T5TmlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFgvQDRibl2u	MXLTRW5ITVJ?
human HT-29 cell	MkTvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NUjPR2dEUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2yPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUxNjR7IH7NMi=>	NUTBd3FoW0GQR1XS
human RKO cell growth	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MUPJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTV{LkCyJI5ONg>?	NIjjb2dUSU6JRWK=
human KY821 cell	M2eweGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MlvhTY5pcWKrdHnvckBw\iCqdX3hckBMYTh{MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWzMlMhdk1w	MlK1V2FPT0WU
human LB1047-RCC cell	NWTDd3BzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M1;PR2lvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTV7Lk[1JI5ONg>?	M3[3VnNCVkeHUh?=
human SW1116 cell	NIPNOFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M3m2[GlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OlAvPDlibl2u	M1XDN3NCVkeHUh?=
human P12-ICHIKAWA cell	NUfCS3NGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M3PldmlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NkKuNlchdk1w	M3zvdnNCVkeHUh?=
human HCC70 cell	NWPCUlZzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MlTBTY5pcWKrdHnvckBw\iCqdX3hckBJS0N5MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[zMlAyKG6PLh?=	NY[0Z2RrW0GQR1XS
human MIA-PaCa-2 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MnrmTY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjNwNUOgcm0v	NWnpSWdUW0GQR1XS
human LoVo cell	NYi3WHdNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NF71Tm5KdmirYnn0bY9vKG:oIHj1cYFvKEyxVn:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22OU4zQSCwTT6=	NU\DdGtUW0GQR1XS
human LB2241-RCC cell	NXzZRpVNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MnTTTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjVwNUKgcm0v	MlTSV2FPT0WU
human GAK cell	M{\MVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M1vpeGlvcGmkaYTpc44hd2ZiaIXtZY4hT0GNIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nk[uPFchdk1w	NXzjT\|d2W0GQR1XS
human RD cell	NYTOUGlTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MoXKTY5pcWKrdHnvckBw\iCqdX3hckBTTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZ5LkGgcm0v	MoHDV2FPT0WU
human KNS-62 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NXXB[YNEUW6qaXLpeIlwdiCxZjDoeY1idiCNTmOtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QS57OTDuUU4>	MlPMV2FPT0WU
human HD-MY-Z cell	MmH4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Mn[yTY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O\|EvOTJibl2u	M{jYfHNCVkeHUh?=
human COR-L105 cell	NX;MW3kzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MWHJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O\|EvPzFibl2u	M{H6OnNCVkeHUh?=
human IA-LM cell	M3HMR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NUTTdYJIUW6qaXLpeIlwdiCxZjDoeY1idiCLQT3MUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVc{NjJ6IH7NMi=>	NUPNRY82W0GQR1XS
human EM-2 cell	M2XiNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M{GwOGlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUe0Mlchdk1w	NEXVeGVUSU6JRWK=
human NB69 cell	NV7kVZB[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MoW0TY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYm=	M2H5OHNCVkeHUh?=
human HuP-T3 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M2T6XWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWSzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFMvQTNibl2u	MmLwV2FPT0WU
human BB30-HNC cell	MljOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Ml\HTY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg2NjVzIH7NMi=>	MoDOV2FPT0WU
human HT-1080 cell	MnXmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M1XSTmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg2Njh6IH7NMi=>	MnTyV2FPT0WU
human RMG-I cell	NYrsUJJ5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NFntVXBKdmirYnn0bY9vKG:oIHj1cYFvKFKPRz3JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFcvOzRibl2u	Ml7hV2FPT0WU
human HCC1419 cell	NYjJcHU2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M{[yOmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUSxPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkyNjN6IH7NMi=>	MkS3V2FPT0WU
human SW780 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NFe0cnlKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVIvOzJibl2u	MXXTRW5ITVJ?
human SNU-387 cell	M{jCfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M3OzSmlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUO4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk{NjN4IH7N	NHG2UZZUSU6JRWK=
human LAMA-84 cell	NGfZSoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MVXJcohq[mm2aX;uJI9nKGi3bXHuJGxCVUFvOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25OE43QCCwTT6=	NGLPS3FUSU6JRWK=
human MV-4-11 cell	NUSydJZQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MULJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25OE44OyCwTT6=	M4fpcHNCVkeHUh?=
human EGI-1 cell	NHj6S3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MkPLTY5pcWKrdHnvckBw\iCqdX3hckBGT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUm1MlgyKG6PLh?=	NH;0XnlUSU6JRWK=
human NCI-SNU-1 cell	M1yxUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M4e3RmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QTZwN{Ogcm0v	M33NWXNCVkeHUh?=
human MEG-01 cell	Ml24S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MYnJcohq[mm2aX;uJI9nKGi3bXHuJG1GTy1yMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUm3Mlc4KG6PLh?=	M4O2XnNCVkeHUh?=
human OMC-1 cell	NW\JcW5uT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NV7OfHU5UW6qaXLpeIlwdiCxZjDoeY1idiCRTVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOC5{MzDuUU4>	NGHLRYtUSU6JRWK=
human NB10 cell	NIOwN2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NITzS2xKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFAvPDJibl2u	MkXsV2FPT0WU
human CAL-62 cell	NH;lXphIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NXrMVZA2UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yODBwN{igcm0v	MVPTRW5ITVJ?
human NCI-H2087 cell	NV\U[plGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MkDjTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yODFwMUSgcm0v	MmjpV2FPT0WU
human MDA-MB-175-VII cell	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			Mne0TY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVc2NV[LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5	NV33[Hh2W0GQR1XS
human LS-513 cell	NXv0VYpOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NWXCNXpxUW6qaXLpeIlwdiCxZjDoeY1idiCOUz21NVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTRwOEOgcm0v	MYXTRW5ITVJ?
human HN cell growth	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			Ml\UTY5pcWKrdHnvckBw\iCqdX3hckBJViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTF{Mj61PUBvVS5?	M4LPbXNCVkeHUh?=
human ABC-1 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M4PJ[GlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlMvODJibl2u	M2PzV3NCVkeHUh?=
human SJSA-1 cell	NXvGW\|VGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MoHZTY5pcWKrdHnvckBw\iCqdX3hckBUUlODLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlMvOTlibl2u	MkDtV2FPT0WU
human PANC1 cells	Moj1SpVv[3Srb36gZZN{[Xl?	MnnvNVAh\|ryP	M{DrU\|EhcA>?	M{XQ[WlvcGmkaYTpc44hd2ZiTVXLNUBqdiCqdX3hckBRSU6FMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4heEW{a{GvNkBt\X[nbDDheEAyOCC3TTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	NFz6cWgzPTd4Nk[zNy=>
human MCF7 cells	M1qxVWZ2dmO2aX;uJIF{e2G7		MYK3OUBucW6\|	MoXCTY5pcWKrdHnvckBw\iCPRXuxM\|IhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKGGodHXyJFc2KG2rboOgZpkhX2W\|dHXyckBjdG:2dHnu[{BidmGueYPpdy=>	M4DobVI{Ozl6NEWz

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / p-AKT / Cyclin D1 / p27; PubMed: 22573716 Cancer Res parental or MEK inhibitor-resistant clonal populations (1182, 1183, and 1187) were treated with increasing doses of PD0325901 for 24 hours and subjected to immunoblot analysis using the indicated antibodies. p-p70S6K(T389) / p4EBP1(S65) / pS6(S235); PubMed: 27699948 Cancer Sci Sensitive (MKN-45, OKAJIMA, HSC-57, GUS, NUGC-4, OCUM-1, SNU-719, and IM95) and resistant (SH-10-TC, MKN-1, HSC-39, NCI-N87, H-111-TC, KE-97, SNU-484, and TMK-1) cell lines were treated with DMSO or PD0325901 (0.1 or 1 μM) for 24 h and then subjected to Western blotting using antibodies against pERK, pAKT, p-p70S6K, p4EBP1, pS6, and GAPDH. cleaved PARP; PubMed: 22573716 Cancer Res NF1-deficient U251 or LN229 GBM cells were treated with PD0325901 for 4 days and subjected to immunoblot analysis using the indicated antibodies. DR5; PubMed: 25867065 Oncogene The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h.	22573716 27699948 25867065
Immunofluorescence	Fibronectin / Actin / pFAK; PubMed: 28187762 BMC Cancer Representative immunofluorescence images of FNMA by GBM-3 cells treated either with DMSO (b) or PD0325901 (c). Fibronectin is depicted in green and DAPI (blue) was used as counterstain. PD0325901 did not appear to induce FNMA by GBM-3 cells. Rhodamine-phalloidin staining of actin in DMSO-treated (d) or PD0325901-treated GBM-3 cells (e). Note significant cell shape change and actin fiber organization. Scale bar in (e) is 5 μm. Triple stain for actin (red), p-FAK (green) and DAPI (blue) in DMSO-treated (f) and PD0325901-treated (g) GBM-3 cells. PD0325901 appears to induce the localization of p-FAK at sites of cell-ECM attachment. Thirty-micron thick z-stack of DMSO (h) and PD0325901-treated (i) collected by confocal microscopy of multicellular aggregates of GBM-3. Note marked change in actin organization from cortical to stress fibers. Scale bar in (i) is 30 μm. ZO-1; PubMed: 25394671 EMBO Rep 16HBE cells were fixed and stained for ZO-1 and DNA. Scale bar, 20 μm.	28187762 25394671

In vivo

The improved potency of PD0325901 relative to CI-1040 is evident. A single oral dose of PD0325901 (25 mg/kg) inhibits phosphorylation of ERK by more than 50% at 24 hours post-dosing. In contrast, CI-1040 at a much higher dose (150 mg/kg) only inhibit pERK levels for roughly 8 hours, returning to control levels by 24 hours after treatment. ^[2] Therefore, the dose required to produce a 70% incidence of complete tumor responses (C26 model) is 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts. ^[2] After 1 week of oral administration of PD0325901 (20–25 mg/kg/day) in mice, no tumor growth is detected in mice inoculated with PTC cells bearing a BRAF mutation. ^[3] For PTC with the RET/PTC1 rearrangement, the average tumor volume of the orthotopic tumor is decreased by 58% as compared with controls. In conclusion, PTC cells carrying a BRAF mutation are more sensitive to PD0325901 than are PTC cells carrying the RET/PTC1 rearrangement. ^[3]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro cascade assay: Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl₂, 1 mM MnCl₂, 1 mM EGTA, 50 mM [gamma-³²P]ATP, 10 mg GST-MEK, 0.5 mg GST-MAPK and 40 mg MBP in a final volume of 100 mL. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. ³²P retained on the filter mat is determined using a 1205 Betaplate. PD0325901 is assessed at various dose ranges in order to determine dose response curves.
Cell Research: ^[3]	+ Expand Cell lines: PTC cells Concentrations: 0.1 nM- 1 μM Incubation Time: 48 hours Method: PTC cells (1 × 10⁴) are seeded in 24-well plates with 1 mL of medium for 4 days in a 37 °C incubator. MEK inhibitor PD0325901 at varying concentrations is added to the cells in triplicate on day 0. MTT dissolved in 0.8% NaCl solution at 5 mg/mL is added to each well (0.2 mL) on day 2 to test GI50 or every day for cell growth curves. The cells are incubated at 37 °C for 3 hours with MTT. The liquid is then aspirated from the wells and discarded. Stained cells are dissolved in 0.5 mL of DMSO and their absorption at 570 nm is measured using a Synergy HT multidetection microplate reader. For GI50, cell growth is calculated as 100 × (T − T₀)/(C − T₀), where T is the optical density of the wells treated with inhibitors after a 48-hour period, T₀ is the optical density at time zero, and C is the control optical density with DMSO only. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: Ncr-nu/nu mice bearing PTC cells Formulation: 80 mM citric buffer (pH 7) Dosages: 20-25 mg/kg Administration: Oral gavage (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	96 mg/mL (199.09 mM)
	Ethanol	40 mg/mL (82.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD0325901 SDF

Molecular Weight	482.19
Formula	C₁₆H₁₄F₃IN₂O₄
CAS No.	391210-10-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02510001	Active not recruiting	Solid Tumor\|Colorectal Cancer	University of Oxford\|Queen''s University Belfast\|Oxford University Hospitals NHS Trust\|Velindre NHS Trust\|University Hospital Antwerp\|Hospital Vall d''Hebron\|Saint Antoine University Hospital\|European Georges Pompidou Hospital\|Pfizer\|University of Turin Italy\|Belfast Health and Social Care Trust\|Beaumont Hospital\|European Commission\|Array BioPharma\|University of Paris 5 - Rene Descartes	November 2014	Phase 1
NCT02510001	Active not recruiting	Solid Tumor\|Colorectal Cancer	University of Oxford\|Queen''s University Belfast\|Oxford University Hospitals NHS Trust\|Velindre NHS Trust\|University Hospital Antwerp\|Hospital Vall d''Hebron\|Saint Antoine University Hospital\|European Georges Pompidou Hospital\|Pfizer\|University of Turin Italy\|Belfast Health and Social Care Trust\|Beaumont Hospital\|European Commission\|Array BioPharma\|University of Paris 5 - Rene Descartes	November 2014	Phase 1
NCT02096471	Completed	Neurofibromatosis Type 1 and Growing or Symptomatic Inoperable PN	University of Alabama at Birmingham	June 2014	Phase 2
NCT02096471	Completed	Neurofibromatosis Type 1 and Growing or Symptomatic Inoperable PN	University of Alabama at Birmingham	June 2014	Phase 2
NCT02039336	Recruiting	Colorectal Cancer	The Netherlands Cancer Institute\|Pfizer	January 2014	Phase 1\|Phase 2
NCT02022982	Active not recruiting	KRAS Mutant Non-Small Cell Lung Cancer\|Solid Tumors	Dana-Farber Cancer Institute	January 2014	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the inhibitor PD0325901 interacts with other targets other than MEK?
Answer:
PD0325901 has very high selectivity to MEK. In addition, it can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA against BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.
Classic MEK Inhibitor

SL-327 : Water soluble MEK1/2 inhibitor, which can cross the blood-brain barrier.

Related MEK Products4

Cobimetinib (GDC-0973, RG7420) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features:Does not inhibit c-Raf phosphorylated MEK1.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features:First MEK inhibitor to begin clinical development.
Binimetinib (MEK162, ARRY-162, ARRY-438162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119, Bay 86-9766)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD0325901

Cited by 138 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD0325901 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Choose Your Country or Region

By Signaling Pathways

By product type

PD0325901

Cited by 138 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD0325901 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)